Key Points
- Director Laurence Charney sold 5,000 TG Therapeutics shares at an average price of $54.96, generating $274,800. The sale reduced his direct holdings by 2.88% to 168,640 shares.
- TG Therapeutics shares opened at $54.00, near their 52-week high of $59.30, with an $8.27 billion market capitalization. The company’s latest quarterly revenue rose 70.2% year over year to $240.34 million, though earnings per share missed estimates.
- Analyst sentiment is mixed, with a consensus “Hold” rating and an average price target of $63.00. Institutional investors own 58.58% of the company’s stock.
TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) Director Laurence Charney sold 5,000 shares of the company's stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $54.96, for a total value of $274,800.00. Following the completion of the transaction, the director directly owned 168,640 shares in the company, valued at $9,268,454.40. The trade was a 2.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
TG Therapeutics Price Performance
Shares of NASDAQ TGTX opened at $54.00 on Tuesday. The firm has a market cap of $8.27 billion, a P/E ratio of 19.71, a price-to-earnings-growth ratio of 2.31 and a beta of 1.67. The business's 50 day moving average is $53.61 and its 200-day moving average is $43.94. The company has a current ratio of 4.27, a quick ratio of 3.72 and a debt-to-equity ratio of 1.23. TG Therapeutics, Inc. has a 1-year low of $26.76 and a 1-year high of $59.30.
TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported $0.05 EPS for the quarter, missing analysts' consensus estimates of $0.31 by ($0.26). The firm had revenue of $240.34 million during the quarter, compared to analyst estimates of $229.77 million. TG Therapeutics had a net margin of 55.22% and a return on equity of 73.49%. The business's quarterly revenue was up 70.2% compared to the same quarter last year. During the same period in the prior year, the company earned $0.17 earnings per share. Equities research analysts predict that TG Therapeutics, Inc. will post 0.92 earnings per share for the current year.
Analyst Upgrades and Downgrades
TGTX has been the subject of several analyst reports. Weiss Ratings reiterated a "hold (c+)" rating on shares of TG Therapeutics in a research note on Wednesday, July 29th. Bank of America increased their target price on shares of TG Therapeutics from $17.00 to $20.00 and gave the stock an "underperform" rating in a research report on Tuesday, July 7th. JPMorgan Chase & Co. raised their target price on shares of TG Therapeutics from $65.00 to $72.00 and gave the stock an "overweight" rating in a report on Friday, August 7th. B. Riley Financial lifted their price target on shares of TG Therapeutics from $55.00 to $86.00 and gave the company a "buy" rating in a research report on Monday, July 27th. Finally, HC Wainwright reiterated a "buy" rating and issued a $78.00 price target on shares of TG Therapeutics in a research report on Tuesday, September 1st. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, TG Therapeutics has a consensus rating of "Hold" and an average price target of $63.00.
Get Our Latest Stock Analysis on TGTX
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of TGTX. EverSource Wealth Advisors LLC lifted its position in TG Therapeutics by 51.9% during the first quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company's stock worth $35,000 after purchasing an additional 365 shares during the period. Hantz Financial Services Inc. increased its holdings in TG Therapeutics by 82.7% in the 4th quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company's stock valued at $37,000 after buying an additional 560 shares during the period. Harbor Investment Advisory LLC bought a new position in TG Therapeutics in the 2nd quarter valued at about $96,000. Covestor Ltd increased its holdings in TG Therapeutics by 563.0% in the 4th quarter. Covestor Ltd now owns 1,810 shares of the biopharmaceutical company's stock valued at $54,000 after buying an additional 1,537 shares during the period. Finally, Pingora Partners LLC raised its position in shares of TG Therapeutics by 31.2% in the 4th quarter. Pingora Partners LLC now owns 2,100 shares of the biopharmaceutical company's stock valued at $63,000 after buying an additional 500 shares in the last quarter. Institutional investors own 58.58% of the company's stock.
About TG Therapeutics
(
Get Free Report)
TG Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for B-cell diseases and autoimmune disorders. The company's research and development programs are centered on therapies that target B cells, which play an important role in several immune-mediated conditions.
TG Therapeutics' principal product is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved by the U.S. Food and Drug Administration for the treatment of adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting multiple sclerosis and active secondary progressive multiple sclerosis.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
